piperaquine

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instance_of gptkb:immunotherapy
gptkbp:administered_by oral tablet
gptkbp:approves gptkb:2007
gptkb:China
gptkb:Vietnam
other Southeast Asian countries
gptkbp:atccode P01 BE02
gptkbp:available_on generic drug
gptkbp:brand gptkb:Piperaquine
gptkbp:can_be_combined_with gptkb:dihydroartemisinin
gptkbp:casnumber 100912-21-4
gptkbp:category gptkb:C
gptkbp:chemical_formula C19 H22 Cl2 N2 O
gptkbp:clinical_trial Phase II
Phase III
gptkbp:clinical_use second-line treatment
first-line treatment
gptkbp:contraindication severe liver disease
severe renal impairment
hypersensitivity to piperaquine
gptkbp:developed_by Chinese pharmaceutical companies
gptkbp:dissolved poorly soluble in water
gptkbp:duration 3 days
7 days
https://www.w3.org/2000/01/rdf-schema#label piperaquine
gptkbp:interacts_with antacids
certain antibiotics
antifungal medications
gptkbp:is_effective_against high against Plasmodium falciparum
high against Plasmodium vivax
gptkbp:is_often_used_in gptkb:artesunate
gptkbp:lifespan approximately 10 days
gptkbp:marketed_as gptkb:Piperaquine_phosphate
gptkbp:mechanism_of_action inhibits heme polymerization
gptkbp:metabolism liver
gptkbp:packaging blister packs
gptkbp:provides_guidance_on WHO recommendations
CDC guidelines
gptkbp:research_focus pharmacokinetics
combination therapies
safety profile
malaria resistance
gptkbp:rounds urine
gptkbp:safety_measures required during treatment
gptkbp:side_effect gptkb:anemia
dizziness
headache
nausea
vomiting
thrombocytopenia
leukopenia
QT prolongation
gptkbp:storage room temperature
gptkbp:used_for treatment of malaria
gptkbp:bfsParent gptkb:artemisinin-based_therapies
gptkbp:bfsLayer 7